Screener
Stoke Therapeutics, Inc. STOK Operating Cash Flow
Operating Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Stoke Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities.
The source filing: Stoke Therapeutics, Inc.’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 4:06 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-211874
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Prepaid expenses and other current assets | (3,588) | (1,230) |
| Accounts payable, accrued liabilities and lease liabilities | (15,719) | 4,741 |
| Deferred revenue | (2,193) | 9,427 |
| Net cash (used in) provided by operating activities | (60,582) | 131,827 |
| Cash flows from investing activities: | ||
| Purchases of marketable securities | (9,853) | (19,016) |
| Purchases of property and equipment | (353) | (152) |
| Proceeds from maturity of marketable securities | 60,900 | 32,800 |
Item 1. Financial Statements.
FAQ
- What is Stoke Therapeutics, Inc.'s operating cash flow?
- Stoke Therapeutics, Inc. (STOK) reported operating cash flow of -$60.58M in Q1 2026.
- How has Stoke Therapeutics, Inc.'s operating cash flow changed year-over-year?
- Stoke Therapeutics, Inc.'s operating cash flow decreased by 146.0% year-over-year, from $131.83M to -$60.58M.
- What is the long-term trend for Stoke Therapeutics, Inc.'s operating cash flow?
- Over 3 years (2021 to 2024), Stoke Therapeutics, Inc.'s operating cash flow has grown at a 9.1% compound annual growth rate (CAGR), from -$66.91M to -$86.85M.
- What does operating cash flow mean?
- Total cash generated by or used in core business operations — the single most important cash flow metric for assessing business health.
Ask your AI about Stoke Therapeutics, Inc.'s operating cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude